Patients in New Zealand, Australia and the Pacific Islands could soon have access to Syndros, one of only four Food and Drug Administration-approved (FDA) cannabinoid medicines.

Greenfern Industries (GFI) is looking to expand its pharmaceutical offering by considering a number of major international deals that would in part provide a pathway to a Schedule 3, over-the-counter registration using a novel cannabinoid medicine for its subsidiary, GFI Pharma. The deals would also provide authorisation for GFI Pharma to distribute Syndros.

Greenfern Industries continues to lead the way both locally and internationally, having been certified a Toitū net carbonzero organisation for the second year in a row. The certification means Greenfern remains New Zealand’s only Toitū net carbonzero certified medicinal cannabis and industrial hemp organisation.

Greenfern, founded on an unwavering commitment to environmental sustainability, is also the only B-Corp certified medicinal cannabis company in New Zealand.

Greenfern Industries has secured a lucrative export deal that could be worth more than $1.6m.

The initial two-year agreement is an offtake order for the purchase of Greenfern’s Taranaki-grown medicinal cannabis.

An offtake agreement is a binding contract that formalises the buyer’s intention to purchase a certain amount of the producer’s future output.

Greenfern Industries Limited is pleased to announce it has attained its globally-recognised GACP (Good Agriculture and Collection Practice) certification for its cultivation facility based in Normanby, Taranaki.

“This is a milestone that the team has been working towards for some time since commencing cultivation and research and development in our pilot stage one facility,” said Greenfern’s managing director Dan Casey.

Greenfern Industries' GMP medicine prescription sales in the Australian market are going from strength to strength.

The company began distribution of its GFI Pharma-branded medicinal cannabis oil tinctures with Australian partner Cannvalate in November 2021. Since then, GFI has seen an average new patient increase of 42% month on month with an average return patient rate of 27% month on month.

Greenfern Industries is the first New Zealand medicinal cannabis company to be awarded B Corp certification gaining an overall finalised score of 86.8.

The company is one of just 83 other Kiwi B Corp businesses, including EcoStore, Cooperative Bank, KiwiBank, Kathmandu, and Synlait.

Certified B Corporations are businesses that meet the highest standards of verified social and environmental performance, public transparency, and legal accountability to balance profit and purpose. They are companies that make decisions to create a positive impact for their workers, customers, suppliers, community, and the environment.